EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis

Jie Dai, Tianxiao Xu, Lifeng Li iD, Meiyu Fang, Jing Lin iD, Jun Cao, Xue Bai, Caili Li, Xiaoting Wei, Junjie Gu, Yaoyao Liu, Xuan Gao und 5 weitere

Clinical and Translational Medicine · 2025

DOI: 10.1002/ctm2.70169 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical and Translational Medicine, 2025. Verfasst von Jie Dai und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Second Hospital of Tianjin Medical University, Tianjin, China. Hauptthemen laut MEDLINE: Bevacizumab, Antibodies, Monoclonal, Humanized, Melanoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Beijing Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atezolizumab plus bevacizumab has shown promising efficacy in advanced mucosal melanoma in the multi‐centre phase II study. This report updates 3‐year survival outcomes and multi‐omics analysis to identify potential response biomarkers.

Methods

Forty‐three intention‐to‐treat (ITT) patients received intravenous administration of atezolizumab and bevacizumab every 3 weeks. Available samples underwent whole exome sequencing, transcriptome sequencing and targeted bisulphite sequencing to assess correlations with clinical outcomes.

Results

With a median follow‐up of 40.3 months, the median overall survival (mOS) was 23.7 months (95% confidence interval [CI], 15.1–34), and the 3‐year OS rate was 28.7% (95% CI, 17.6%–46.8%). Patients with upper site melanoma exhibited longer progression‐free survival (PFS), higher tumour neoantigen burden (TNB) and greater copy number variations (CNVs) burden compared to those with lower site melanoma. NRAS mutations were associated with enhanced angiogenesis, with five of six patients achieving partial response. Inflammatory cell infiltration, angiogenic status and activation of the SMAD2 and p38 MAPK pathways may be prognostic indicators.

Conclusions

This 3‐year updated analysis confirms the sustained efficacy of atezolizumab in combination of bevacizumab in patients with advanced mucosal melanoma. Inflammatory cell infiltration and angiogenic status were associated with therapeutic response. Furthermore, mucosal melanoma of upper site and NRAS mutation appear to be good predictors of response to immune checkpoint inhibitor and anti‐angiogenic combination treatment. Targeting SMAD2 and p38 MAPK pathways may further improve the outcome of mucosal melanoma. Key points 3‐year follow‐up study confirmed the therapeutic efficacy of atezolizumab combined with bevacizumab Tumors in the upper site and NRAS mutations are more sensitive to treatment Inflammatory cell infiltration, angiogenic status, and activation of the SMAD2 and p38 MAPK pathways may be prognostic indicators

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabAntibodies, Monoclonal, HumanizedMelanomaAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedAdultMucous MembraneMultiomicsMembrane ProteinsGTP Phosphohydrolases

Stichwörter der Autor:innen

VEGF inhibitoratezolizumabbevacizumabimmunotherapymucosal melanoma

Substanzen

BevacizumabAntibodies, Monoclonal, HumanizedatezolizumabNRAS protein, humanMembrane ProteinsGTP Phosphohydrolases

Autor:innen und Institutionen

  • Department of Urology, Second Hospital of Tianjin Medical University, Tianjin, China.
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China.
  • Geneplus-Beijing, Beijing, China.
  • Department of Rare Cancer & Head and Neck Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, Key Laboratory of Head & Neck Cancer Translational Research of Zhejiang Province, Hangzhou, C…
  • Department of Medical Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fujian, China.
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital and Institute, Beijing, China.

ORCID-Profile: Lifeng Li, Jing Lin, Yu Chen, Lu Si

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Beijing Natural Science Foundation
  • Beijing Municipal Administration of Hospitals' Ascent Plan
  • Beijing Research Ward Excellence Program (BRWEP)
  • National Basic Research Program of China
  • Natural Science Foundation of Beijing Municipality

Zitieren

APA

Dai, J., Xu, T., Li, L., Fang, M., Lin, J., Cao, J., Bai, X., Li, C., Wei, X., Gu, J., Liu, Y., Gao, X., Xia, X., Guo, J., Chen, Y., Mao, L., & Si, L. (2025). Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70169

Vancouver

Dai J, Xu T, Li L, Fang M, Lin J, Cao J, et al. Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis. Clinical and Translational Medicine. 2025. doi:10.1002/ctm2.70169

BibTeX
@article{Dai2025,
  author = {Dai, Jie and Xu, Tianxiao and Li, Lifeng and Fang, Meiyu and Lin, Jing and Cao, Jun and Bai, Xue and Li, Caili and Wei, Xiaoting and Gu, Junjie and Liu, Yaoyao and Gao, Xuan and Xia, Xuefeng and Guo, Jun and Chen, Yu and Mao, Lili and Si, Lu},
  title = {Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis},
  journal = {Clinical and Translational Medicine},
  year = {2025},
  doi = {10.1002/ctm2.70169}
}
Kostenlos starten →